Skip to content

PHARMA-BIO SERV, INC.: 10-Q filed 2026-09-14

What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2026-09-14 (fiscal Q3 2026): 37 published measures, 124 facts as tagged in accession 0001654954-26-008346.

This filing

Form
10-Q (quarterly report)
Filed
2026-09-14
Fiscal period
fiscal Q3 2026
Accession
0001654954-26-008346 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-07-3111,439,648USD
At 2025-10-3113,653,046USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-07-31994,740USD
At 2025-10-311,738,799USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-07-3110,444,908USD
At 2026-04-3010,454,229USD
At 2025-10-3111,914,247USD
At 2025-07-3111,926,684USD
At 2025-04-3012,123,308USD
At 2024-10-3113,715,327USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-14,219USD92
2025-11-01 to 2026-07-31251,627USD273
2025-05-01 to 2025-07-31-204,250USD92
2024-11-01 to 2025-07-31-100,361USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-05-01 to 2026-07-3160,892USD92
2025-11-01 to 2026-07-31-694,558USD273
2025-05-01 to 2025-07-31236,524USD92
2024-11-01 to 2025-07-31-494,552USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-05-01 to 2026-07-311,390USD92
2025-11-01 to 2026-07-316,122USD273
2025-05-01 to 2025-07-312,036USD92
2024-11-01 to 2025-07-316,294USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-05-01 to 2026-07-312,336,055USD92
2025-11-01 to 2026-07-317,333,964USD273
2025-05-01 to 2025-07-311,963,083USD92
2024-11-01 to 2025-07-316,851,460USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-05-01 to 2026-07-310USD92
2025-11-01 to 2026-07-31-1,720,017USD273
2025-05-01 to 2025-07-31-5,004USD92
2024-11-01 to 2025-07-31-1,742,159USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-326,303USD92
2025-11-01 to 2026-07-31553,310USD273
2025-05-01 to 2025-07-311,628,780USD92
2024-11-01 to 2025-07-31-609,726USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-07-319,067,589USD
At 2025-10-3110,533,589USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-05-01 to 2026-07-3122,901,692shares92
2025-11-01 to 2026-07-3122,904,543shares273
2025-05-01 to 2025-07-3122,927,283shares92
2024-11-01 to 2025-07-3122,947,743shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-05-01 to 2026-07-3122,910,637shares92
2025-11-01 to 2026-07-3122,912,581shares273
2025-05-01 to 2025-07-3122,937,921shares92
2024-11-01 to 2025-07-3122,955,581shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-0.001USD/shares92
2025-11-01 to 2026-07-310.011USD/shares273
2025-05-01 to 2025-07-31-0.009USD/shares92
2024-11-01 to 2025-07-31-0.004USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-05-01 to 2026-07-313,121USD92
2025-11-01 to 2026-07-3113,118USD273
2025-05-01 to 2025-07-31-4,779USD92
2024-11-01 to 2025-07-311,847USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-07-3180,060USD
At 2025-10-31116,059USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-05-01 to 2026-07-318,620USD92
2025-11-01 to 2026-07-3125,858USD273
2025-05-01 to 2025-07-319,999USD92
2024-11-01 to 2025-07-3130,680USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-71,812USD92
2025-11-01 to 2026-07-31-21,671USD273
2025-05-01 to 2025-07-31-313,877USD92
2024-11-01 to 2025-07-31-504,390USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-07-3111,238,835USD
At 2025-10-3113,386,845USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-07-31994,740USD
At 2025-10-311,738,799USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-07-312,421,459USD
At 2025-10-312,360,682USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2026-05-01 to 2026-07-310USD92
2025-11-01 to 2026-07-312,390USD273
2025-05-01 to 2025-07-315,004USD92
2024-11-01 to 2025-07-3122,241USD273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-05-01 to 2026-07-31691,734USD92
2025-11-01 to 2026-07-312,316,149USD273
2025-05-01 to 2025-07-31574,262USD92
2024-11-01 to 2025-07-312,161,097USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-05-01 to 2026-07-311,644,321USD92
2025-11-01 to 2026-07-315,017,815USD273
2025-05-01 to 2025-07-311,388,821USD92
2024-11-01 to 2025-07-314,690,363USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2026-05-01 to 2026-07-31763,546USD92
2025-11-01 to 2026-07-312,337,820USD273
2025-05-01 to 2025-07-31888,139USD92
2024-11-01 to 2025-07-312,665,487USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-07-3122,901,692shares
At 2025-10-3122,905,992shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-07-311,518,314USD
At 2026-04-301,791,474USD
At 2025-10-313,379,212USD
At 2025-07-313,957,752USD
At 2025-04-302,093,075USD
At 2024-10-316,767,356USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-07-311,705,405USD
At 2025-10-311,679,547USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-07-31251,238USD
At 2025-10-31278,045USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-07-310USD
At 2025-10-3129,388USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-07-31176,413USD
At 2025-10-31199,929USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-07-31120,753USD
At 2025-10-31120,754USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-07-31240,225USD
At 2025-10-31171,574USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-11,098USD92
2025-11-01 to 2026-07-31264,745USD273
2025-05-01 to 2025-07-31-209,029USD92
2024-11-01 to 2025-07-31-98,514USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-17,941USD92
2025-11-01 to 2026-07-31224,820USD273
2025-05-01 to 2025-07-31-201,619USD92
2024-11-01 to 2025-07-31-77,164USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-05-01 to 2026-07-3160,714USD92
2025-11-01 to 2026-07-31286,416USD273
2025-05-01 to 2025-07-31104,848USD92
2024-11-01 to 2025-07-31405,876USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2026-05-01 to 2026-07-310USD92
2025-11-01 to 2026-07-31661,728USD273
2025-05-01 to 2025-07-310USD92
2024-11-01 to 2025-07-31528,746USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-05-01 to 2026-07-31-295,791USD92
2025-11-01 to 2026-07-3159,302USD273
2025-05-01 to 2025-07-31-675,376USD92
2024-11-01 to 2025-07-31-551,482USD273

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))